Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 8

Emerging utility of once-weekly exenatide in patients with type 2 diabetes

Authors Goud A, Zhong J, Rajagopalan S

Received 25 May 2015

Accepted for publication 29 August 2015

Published 21 October 2015 Volume 2015:8 Pages 505—512

DOI https://doi.org/10.2147/DMSO.S69354

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Prof. Dr. Ahmed R. G.

Peer reviewer comments 2

Editor who approved publication: Professor Ming-Hui Zou


Aditya Goud, Jixin Zhong, Sanjay Rajagopalan

Division of Cardiovascular Medicine, Department of Medicine, University of Maryland, Baltimore, MD, USA

Abstract: Type 2 diabetes mellitus (T2DM) is a major risk factor for the development of cardiovascular disease (CVD). Due to the ever increasing incidence of both T2DM and CVD and coexistence of these disorders, numerous agents have been developed over the years to target complications. We focus on the efficacy and safety perspective of a long-acting formulation of the glucagon-like peptide-1 analog exenatide. Our review focuses on the various landmark trials, efficacy, safety profile, and patient perspectives of weekly exenatide that delineates its current and future role in the treatment of patients with T2DM and CVD.

Keywords: incretin, glucagon-like peptide, hyperglycemia, glucose lowering

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]